You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
|
|---|---|
| Published in |
Journal of Hematology & Oncology, December 2017
|
| DOI | 10.1186/s13045-017-0541-9 |
| Pubmed ID | |
| Authors |
Bingshan Liu, Yongping Song, Delong Liu |
| Abstract |
Antibodies against programmed death (PD) pathway are revolutionizing cancer immunotherapy. Currently five antibodies against PD-1/PD-L1 have been approved. The clinical use of these antibodies is rapidly expanding. Incorporation of PD antibodies into chemotherapy regimens is in active clinical investigations. The combination of pembrolizumab with carboplatin and pemetrexed has been approved for the first line therapy of metastatic non-squamous non-small cell lung cancer. Combination of PD-1/PD-L1 antibodies with small molecule inhibitors such as tyrosine kinase inhibitors and IDO inhibitors are in active clinical trials. This review summarized recent development in clinical trials of PD-1 and PD-L1 antibodies for cancer immunotherapy. |
Mendeley readers
The data shown below were compiled from readership statistics for 102 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 102 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 14 | 14% |
| Student > Master | 13 | 13% |
| Researcher | 12 | 12% |
| Student > Ph. D. Student | 10 | 10% |
| Other | 8 | 8% |
| Other | 17 | 17% |
| Unknown | 28 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 25% |
| Pharmacology, Toxicology and Pharmaceutical Science | 13 | 13% |
| Biochemistry, Genetics and Molecular Biology | 12 | 12% |
| Agricultural and Biological Sciences | 6 | 6% |
| Nursing and Health Professions | 5 | 5% |
| Other | 9 | 9% |
| Unknown | 31 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 August 2022.
All research outputs
#5,304,682
of 25,323,244 outputs
Outputs from Journal of Hematology & Oncology
#449
of 1,288 outputs
Outputs of similar age
#103,922
of 451,644 outputs
Outputs of similar age from Journal of Hematology & Oncology
#7
of 18 outputs
Altmetric has tracked 25,323,244 research outputs across all sources so far. Compared to these this one has done well and is in the 78th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,288 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.4. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 451,644 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.